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Antibodies to the blood group A and B substances in human sera are extra- 
ordinarily heterogeneous.  Sera generally contain vG, ~,M, and ~A anfi-A or 
anti-B  (1-6). Differences in properties of various sera by precipitation  (4, 5), 
hemagglutination  (4,  5,  7-9),  hemolysis  (8,  10,  11),  complement  fixation, 
(10-12) and fixation to skin (4, 13) have been found. To understand the extent 
of this heterogeneity it is essential  to prepare and study blood group antibodies 
of the various immunoglobulin classes from single donors. In an earlier  study 
from this laboratory (5), insoluble  blood group A and B substances were pre- 
pared  by attaching  polyleucyl side chains  to them,  using  the N-carboxyan- 
hydride method (14). Large volumes of anti-A could be specifically absorbed on 
these products and, after washing to remove nonspecific protein, a considerable 
proportion of the antibody was eluted with N-acetylgalactosarnine (GalNAc). 
This eluate could be fractionated into ~,M anti-A and ~,G anti-A;  these two 
anti-A fractions showed striking differences with respect to the relative capac- 
ities of mono- and oligosaccharides  to inhibit precipitation by antigen. With the 
~,G anti-A, a reduced pentasaccharide was a much better inhibitor on a molar 
basis than a trisaccharide which in turn was better than N-acetylgalactosamine, 
while with the ~,M anti-A, all three compounds were equally potent (5). 
The present study extends these observations, adding the characterization of 
a  second population  of antibodies obtained by eluting with a  specific blood 
group A pentasaccharide (ARs0.52) the anti-A antibodies which had remained 
absorbed on  the insoluble antigen  after  elution with N-acetylgalactosamine. 
* Aided  by  grants  from  the National Science Foundation  (GB-3675 and 8341) and  the 
General Research Support Grant of the United States Public Health Service. 
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Studies  by  inhibition  of  precipitation  have  been  correlated  with  association 
constants  determined  by equilibrium dialysis.  Other properties  of the various 
antibody fractions including hemagglutination,  complement fixation, hemolytic 
activity, and kinds of light chains are also reported. 
Materials and Methods 
Antisera--Subject  1 (blood group O+): Received two immunizations of 1 mg hog mucin 
blood group A  +  H  substance  1 day apart in 1945, and a second  course of 2 mg, 5 months 
later (15). A very slow decrease in anti-A titer has been observed through all these years (16). 
Two consecutive bleedings,  D33 and D~4,  taken in February 1963 were pooled and studied. 
Subjects, Jos. (B+) and Chris.  (O+), were immunized with two injections of 1 mg commercial 
hog mucin A blood group substance (Pfizer Diagnostics, New York). 1 Two bleedings were ob- 
tained from each donor. 
Anti-A serum 59-113  (17) with high agglutinating titer, was used routinely for inhibition 
of agglutination. Eel anti-H serum (18), a gift from Dr. Georg Springer, Northwestern Uni- 
versity, and seed extract from Ulex europeus (19) were used to test H activity by inhibition of 
agglutination. Rabbit and goat antisera to human -rG, ~,M, and 7A immunoglobulins and to 
whole human serum were purchased from Hyland Laboratories, Los Angeles, Calif., and from 
Lloyd Brothers, Inc., Cincinnati, Ohio.  Rabbit anti-human ~ and X chain sera were donated 
by Dr. Henry G. Kunkel of Rockefeller University. 
Blood Group Substances (BGS)--Hog mucin blood group substance with A and H  activities 
was  purified  from commercial hog gastric  mucin  (Wilson  Laboratories,  Chicago,  Ill.)  by 
ethanol precipitation, as previously described (20). 
Insoluble polyleucyl blood group A substance  (PLA) was prepared from the purified hog 
mucin in B GS by coupling with 2g-carboxyleucylanhydride (Pilot Chemicals Inc., Watertown, 
Mass.) (5). Human A substance (MSM) has been described previously (21). 
Carbohydrates--N-acetyl-D-galactosamine (GalNAc)  and N-acetyl-D-glucosamine (GNAc) 
were purchased from Nutritional Biochemical Corp., Cleveland. I,-fucose (Fue) and D-galactose 
(GaD were from Mann Research Laboratories, New York. AsH, a trisaccharide with A activity 
was isolated earlier from acid hydrolysates of BGS (17). Its structure is: 
a-D-GalNAc-(1 --~ 3)-fl-D-Gal-(1 ~  3)-D-GNAc 
ARL0.52 pentasaccharide, also A active, has been described (22, 23). It has the structure: 
c~-L-Fuc 1 
2 
a-D-GalNAc-(1 --~ 3)-~-D-Gal-(1 ~  4)-/~-D-GNAc-(1 --* 6)-R 
in which R  represents a mixture of hexenetetrols CH2OH--CHOH--CH=CH--CHOH-- 
CH2OH formed by alkaline borohydride degradation from a  Gal residue  (24).  This penta- 
saccharide was purified according to the following procedure: 28 g of hog mucin blood group 
substance  (A +  H  active) were added to 280 ml of a 0.2 ~1 NaOH-1% sodium borohydride 
solution. The material went into solution and was stirred for 2 days at 4°C and for 5 days at 
room temperature. After neutralization the product was dialyzed, the dialysate concentrated 
by evaporation at reduced pressure and desalted by adding 320 g of mixed resin (Amberlite 
M_B 3). The desalted dialysate (14.5 g) was fractionated in a charcoal-celite column (320 mm X 
I We thank Dr. R. E. Rosenfield,  Mount Sinai Hospital, New York, for his collaboration in 
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80 ram) containing 350 g charcoal and 175 g celite (25). The col.mn was eluted with water 
and then with an ethanol gradient 0-70% ethanol. 
Ollgosaccharides were located by periodate uptake and paper chromatography (23). 
ARL0.52  is eluted at an ethanol concentration of approximately 15%, but location of the 
peak  by periodate uptake  is anomalous since on oxidation it gives products  absorbing  at 
225 m#  2 and the phenol-sulfuric acid method (26) must be used. 
The fraction rich in ARL0.52,  2.04 g, was applied to 15 sheets of chromatographic paper 
(S and S paper No. 589 Green Label) and run for 20 hr in butanol, pyridine, water, 6:4:3. 
The papers were cut as determined from small strips. Oligosaccharides were eluted with water, 
lyophillzed, and chromatographed on a Bio-Gel P2 col,  mn (820 mm X  19 ram), during with 
water.  A  small shoulder of a  flower-moving compound was eliminated and those fractions 
showing only one component, ARL0.52, by paper chromatography were pooled and analyzed. 
This fraction, ARL0.52  (345 rag)  was then repurified on a charcoal-celite column (450 mm X 
28 mm) as above. The main peak, containing the pentasaccharide ARL0.52  (197 rag) gave a 
single spot on paper chromatography and analysis of sugars as expected from the formula. 
This material was used to elute anti-A antibodies from the columns of PLA-BGS and to pre- 
TABLE I 
Analytical ProtJerties of 'H-ARLO.SZ Pentasacckaride 
Found 
Expected 
Total N 
% 
3.3 
3.2 
Methyl- 
pentose 
% 
18.3 
19.2 
Galactose 
% 
20,8 
20.9 
Hexosamlne 
% 
37.8 
41.5 
NAc hex- 
osall~e 
% 
30.2 
Molar ra~o 
NAc hexosamine 
hexosamine 
0.65 
0.65 
pare tritlated ARL0.52; the ARL0.52 was recovered and  repurified on a charcoal-celite column 
after each experiment. 
Labeling of ARLO.52--Tbis was  accomplished by taking  advantage  of the unsaturated 
character of the residue (R) at the reducing end of ARL0.52.  100 mg of ARvD.52 were sent to 
New England Nuclear Corp., Boston, Mass., to  be reduced catalytically in the presence of 
3c of tritium gas. The compound was purified in this laboratory by the following procedure. 
One-half of the sample was passed through a column of Bio-Gel P  2  (770 mm X  19 ram). 
Although a single,  rather symmetrical radioactive peak was obtained, the nonconstant ratio 
of radioactivity to sugar content  (estimated by the phenol-sulfuric method)  suggested the 
presence of several components. This was confirmed by paper chromatograms and locating the 
radioactivity in a  Packard  scanner type counter, equipped with gas-flow  counter and open 
window) Therefore, the sample was purified twice by preparative paper chromatography as 
described above for the nonradioactive compound ARL0.52. The product was then repurified 
passing it through a Bio-Gel P 2 column. The single sharp peak from the column gave a single 
radioactive peak (97% of total area) on paper chromatograms with a mobility exactly the same 
as the nonradioactive ARL0.52,  and gave satisfactory analytical values and was used for all 
the studies. (Table I). 
The other half of the sample from New England Nuclear Corporation was purified passing 
2 Moreno, Carlos,  and Elvin A. Kabat. Unpublished observation. 
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it four times through a  charcoal-celite column to give  a  compound with analytical values 
equivalent to the other portion. From 100 mg ARL0.52,  a  total of  11.6 mg of aH-ARz0.52 
were obtained with a specific activity of 6.89 X  108 cpm/~mole. 
Analytical Methods--The following methods were used: Total nitrogen (21); periodate up- 
take  (27); phenol-sulfuric reaction (26).  Hexosamine, NAc hexosamine, methylpentose, and 
hexose (galactose) determination were performed as described in (27). 
Paper Chromatography--Descendiug paper  chromatography  on  Schleicher  and  Schuell 
No.  589 green ribbon was used  analytically and preparatively with butanol-pyridine-water 
(6:4:3) as eluant (23). 
Density Gradient Centrifugation--Linear 10--40%  sucrose  gradients  in  saline-phosphate 
buffer were used to separate 3,G from 3,NI antibodies (28).  An SW 25.1  rotor with adaptors 
was used for small volumes (33 Jar, 22,500 rpm) and an SW 41 (24 hr, 30,000 rpm) when larger 
volumes were centrifuged.  Density gradients were  similar to those described  in reference 5. 
Assays for  Tritium--Counting  of  radioactive samples was  done in  a  Packard  Tri-Carb 
liquid scintillation counter using 10 ml of Bray's solution per vial (29).  Light activation was 
avoided and an external  standard was used  to estimate the amount of quenching in each 
sample. Blanks and reference solutions with known amounts of radioactivity were included. 
Each sample was always counted twice,  4 often in two different counters. 
Immunochemioal Methods--Quantitative precipitin assays and quantitative inhibition as- 
says were performed as described  (17).  Hemagglutination and hemagglutination inhibition 
were carried out using Takatsy microtitrators (Cooke Engineering Co., Alexandria, Va.) (5). 
Titrations of antibody fractions from a given serum were performed simultaneously. A micro- 
method for double diffusion in agar was used (27). Quantitative radial immunodiffusion (30, 
31) using immunoplates (Hyland Laboratories) was employed to estimate the 3,G, 3,A, and 
~M content of immunoglobulin fractions. Purified immunoglobulins were used as standards 
and several concentrations of unknown and standard were included in each plate. Estimation 
of immunoglobulin content was made graphically by plotting (radius)  ~ vs. concentration. 
lmmunodectrophoresis---Performed according to Grabar and Williams (32). 
Hemolysis--Hemolysis assays were done as described in (33). 
C' Fixation--The  method of Wasserman and Levine (34)  was used.  C' fixation was per- 
formed only with purified antibody. Incubation time for fixation was 30 rain at 37°C and over- 
night at 4°C; 2C'H50 units per tube were used, enough to reach approximately 90% lysis in the 
control tube.  Guinea pig C', sheep red cells,  and hemolysin were purchased from  Baltimore 
Biological Laboratories, Baltimore, Maryland. 
Equilibrium Dialysis--This  procedure was carried out using glass cells manufactured by 
Buchler Instruments. Fort Lee, N.J. Incubation for 80 hr at 25°C was required for equilibrium. 
The method as well as the description of the cells can be found in (27). The total volume per 
chamber was 1 ml. Aliquots from both sides, in duplicate, were taken and counted. 
Purif~ation of Antibodies--As described previously (5), purification of antibodies was done 
with insoluble polyleucyl blood group A +  H substance as immunoadsorbent. After centrifuga- 
tion at 2000 rpm for several days, the clarified serum was passed through a small column of 
PLA mixed with celite in a ratio of 1: 6. Absorption of antibodies was followed by agglutinatio- 
titer of the effluent. The entire procedure was carried out at 4°C. A tendency of the column to 
stop flowing was noticed if the column was not wide enough (ratio length to diameter should 
be <6) and ff analytical grade celite was used to prepare the column. After absorption of anti- 
bodies,  the column was  extensively washed with saline buffer pH  7.2,  until practically no 
material absorbing at 280 m~ was detected in the washings. 
Elution with GalNAc was then performed by letting a  10% solution of  GalNAc (in saline 
buffer) penetrate the column and incubating for 1 hr at 37°C. The column was drained, washed 
with saline buffer at 4°C,  the eluate concentrated by ultrafiltration (Schleicher and  Schuell 
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collodion bags) under reduced pressure and then passed through a column Of Bio-Gel P  10 
(820 nun X  19 ram) to eliminate GalNAc. Elution with GalNAc  under the same conditions 
was repeated until essentially no (or very little) antibody was recovered, indicating that anti- 
body capable of being eluted with the GalNAc  had already been removed. All antibodies eluted 
with GalNAc  from a given column  were pooled and will be referred to as GalNAc  eluates. 
After this extensive extraction with GalNAc, ARL0.52 pentasaccharide was used to elute 
(the amounts will be given for each experiment) the remaining antibody from the column. 
Incubation was at 37°C for I hr and the eluates were concentrated in the same way. The 
limited amount of ARL0.52 available did not permit successive elutions, and therefore, the 
first 10 ml of ultrafiltrate obtained during the concentration of the first eluate with ARL0.52 
were used for a second extraction under the same conditions. The two eluates were pooled, 
concentrated, and dialyzed. Passage  twice through  a columnof  Bio-Gel  P 10 (820 mm X 19 ram) 
eliminated all the residual ARL0.52  bound to the antibody  as demonstrated by absence of sugar 
in the included volume  of the column. 
RESULTS 
The procedure used to fractionate the antibodies from the whole serum is il- 
lustrated in Fig. 1. The same procedure was used with all three of the six anti-A 
sera fractionated, except for the last elution at high concentrations of salt. For 
serum 1, 2 •  NaI was used and for serum Jos., successive elutions with 0.5, 1, 
2, and 4 M KCNS were used (35, 36). Although all the eluates obtained with 
NaI and KCNS contained some small amount of protein, none had more than 
traces of agglutinating activity. No elution at high salt concentration was at- 
tempted with Chris. antiserum. 
The yields of antibody absorbed on the column, the amount of hapten used 
to elute and the recoveries in each eluate are given in Table II. The efficiency 
of the absorption was measured by the amount of precipitating antibody re- 
maining in the antiserum after passing it through the column. With serum 1, 
which had only 86 % of the antibody absorbed, the 14 % remaining was easily 
taken out by passing the serum through a second column of PLA. The absorp- 
tion from antisera Jos. and Chris. was 97 and 100 % respectively. 
The amount of GalNAc used for elution, as indicated in Table II, was the 
quantity needed to take out all the antibody capable of being eluted by several 
additions of this sugar. The amount of pentasaccharide ARL0.52 used for e|u- 
tion was determined by the amount available at the time of the experiment. 
With respect to recovery of purified antibody, Table II gives two values for 
the antibody content of antiserum 1, one obtained with hog, and the other, with 
human blood group A  substance. This is because, while this work was under 
way, it was found that this particular antiserum had antibodies to a  "non-A" 
determinant present in hog, but not in the human, blood group materials. This 
antibody amounts to approximately 30 % of the total precipitated by hog sub- 
stance  5 and it all remained absorbed in the column. The estimate of the total 
5 Moreno, C., and E. A. Kabat.  1969. Immunochemical studies on blood groups. XLIV. 
Human antibodies against a  new determinant present in blood group substance from hog 
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amount of antibody recovered by elution from the column was therefore calcu- 
lated from the human blood group substance assays. The total yields of anti- 
body ranged from 72 % for sermn 1 to 49% for serum Jos., and there were sub- 
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FIG. 1. Scheme of antibody fractionation. 
stanfial differences among the sera with respect to the amount of antibody ob- 
tained in each eluate. For sera 1 and Jos., the bulk of the antibody was obtained 
in the GalNAc eluate. For serum Chris.,  the yield of antibody obtained in the 
ARt.0.52 eluate (31%) was very close to that in the GalNAc eluate (34%). CARLOS MORENO AND  ELVIN  A.  KABAT  877 
The composition  of the GalNAc and ARL0.52 eluates,  listed in Table III, 
reveals that although all three sera contained  ~G, ~A, and ~M antibodies, their 
relative concentrations varied substantially. The GalNAc eluate of serum I was 
very rich in ~,M (46 %), but this immunoglobulin was practically absent from 
the ARL0.52 eluate of the same serum. With both serum I and Jos., practically 
all the vM antibody was present in the GalNAc eluate; the AR~0.52 eluates of 
TABLE II 
Recoveries of Antibody in Fractions F.luted  from PLA Columns 
Serum 
.~o. 1 
los. 
~hris. 
Volume 
rid 
2,084 
233 
222 
Antibody 
concen- 
tration  in 
serum 
~g  N/ml 
9.0* 
6.2§ 
65.5 
38.8 
Amount 
mg 
576 
4OO 
400 
Antibody 
absorbed 
% 
86 
96 
100 
Amount Recovery 
Ga~Ac  of anti-  body in 
used to  GalNAc 
elute  eluste 
%of 
g  absorbed 
7  38* 
56§ 
5  35 
2  34 
Amount of 
ARL0.52 
pentasac- 
charide used 
to elute 
mg 
200~ 
170~ 
sot 
Recovery 
of anti-  Total 
body in 
ARL0.52  recovery 
eluate 
%  % 
11"  49* 
16§  72§ 
14  49 
31  65 
* Tested with hog A +  H blood group substance. 
t Passed twice through the column. 
§ Tested with human A (MSM) blood group substance. 
TABLE III 
Composition of the E.luates Obtained  from PLA Columns 
GalNAc eluate  ARL0.52 eluate 
Serum 
~A  ~,G  7A  ~M 
No. I 
Jos. 
Chris. 
% 
46 
94 
% 
12 
traces 
traces 
vM 
% 
46 
14 
29 
% 
100 
100 
89 
% 
traces 
traces 
traces 
% 
traces 
traces 
18 
these two sera contained almost exclusively ~G. With serum Chris., 18 % of the 
ARL0.52 was ~M, a quantity not much lower than the 29% of yM obtained in 
the GaINAc eluate of the same serum. The GalNAc eluate of serum I differed 
from the corresponding eluate of the other sera in two respects:  the yM con- 
tent was very high (46%)  and it was the only one in which there was enough 
yA for quantitative estimation. 
Figs. 2 a, 2 b, and 2 c present the results of quantitative precipitin  studies 
with antisera I, Jos., and Chris., respectively. Except for the ~G GaINAc eluate 878  HUMAN  ANTIBODIES  AND  BLOOD GROU'P  A  SIYBSTANCE 
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FIG. 2. Quantitative precipitin curves of anti-A sera and purified anti-A antibodies. 
(a).  Serum No.  1.  X,  297 #1 unabsorbed serum;  ®,  1.0 ml absorbed serum  (PLA);  Q, 
5.46 #g N GalNAc eluate; O, 5.40 #g N vG GalNAc eluate; A, 4.75 #g N 7M GalNAc eluate; 
I,  6.80/~g N ~G ARL0.52  eluate. 
(b).  Serum  Jos.  X,  74.7 #1 unabsorbed serum;  ®,  0.494 #1 absorbed serum  (PLA); O, 
5.55 #g I~ GalNAc eluate; O, 6.30 #g N vG GalNAc eluate; A, 5.05 #g N 7NI GalNAc eluate; 
!  5.45 #g N 7G ARL0.52  eluate. 
(c).  Serum Chris.  X,  150.3/A unabsorbed serum;  ~,  1.0 ml absorbed serum (PLA); O, 
7.88 #g l~ GalNAc eluate; I,  6.44 #g N ARL0.52  eluate;  O, 4.40 #g N -¢G GalNAc eluate; 
A, 4.16 #g N ~,M GalNAc eluate; ~7, 4.20 #g N "rG ARL0.52  eluate; VI, 3.86 #g N ~¢NI ARL0.52 
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d  serum 1 (Fig. 2 a) all the sera and eluates that were studied in the zone d 
antigen excess did not show substantial solubility of the complex in moderate 
antigen excess. The point d  maximum precipitation was used to estimate the 
percentage  d  precipitating  antibody in  each  eluate.  These data  (column 3, 
Table IV)  show  the  substantial  variation  ha  precipitating  capacity of  these 
TABLE IV 
Some Properties of Purified Human Anti-A Antibodies 
Antibodies 
from serum 
~erum 1 
~erum Jos. 
3erum Chris. 
Antibody fraction 
"rG GalNAe eluate 
7M GalNAc eltmte 
7G ARL0.52 eluate 
7G GalNAc eluate 
"rM GalNAc eluate 
"rG ARL0.52 eluate 
7G GalNAc eluate 
~,M GalNAc eluate 
7G ARL0.52 eluate 
7M ARL0.52 eluate 
Precip,  itating 
antibody 
total protein 
% 
43 
68 
61 
59 
69 
loo 
74 
80 
86 
74 
Minimum 
concentration 
for hemag- 
glutination 
~g N/ra 
0.2 
0.7 
0.04 
Complement 
fixing capacity 
Hemol~(tic 
capactty 
Amount  (tested on 
of anti- ' C' fixed  A* RBC) 
body 
used 
mt,g N  %  mpg N 
210  51  900* 
3OO  94 
320  13:~  2000* 
720  12~ 
210  0  1800" 
9OO  84 
0.3  1060  0 
0.001  2200  § 
0.01  310  14 
940  34 
1.0  300  40  >264[[ 
4OO  69 
0.01  400  §  18[[ 
0.4  260  58  >27411 
310  73 
0.007  390  46  18[[ 
620  81 
* Antibody N giving 40% lysis. 
~: Hog (A +  H) BGS was used as antigen. 
§ Gave lysis in control tubes with nonsensitized sheep red blood cells. 
[[ Antibody N giving 50% lysis. 
fractions. 7G  GalNAc,  of serum  1,  is only 43 %  precipitating  antibody. 7G 
ARL0.52  of Jos.  was completely precipitated  by antigen.  The  others  ranged 
between these two. 
Complement fixation  assays on  these  purified  antibodies  with  soluble hog 
(A q- H) or human MSM as antigens are presented in Figs. 3 a, 3 b, 3 c. Fig. 3 a 
gives results with eluates from semrn 1.94% of the C' was fixed by 300 m/~g 
of  the  purified  7G  antibody  from  the  GalNAc  eluate  while  the  -yM  of 880  HUMAN  ANTIBODIES  AND  BLOOD  GROUP  A  SUBSTANCE 
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the  same  eluate  fixed  only  13%,  using  284  mug  of  antibody  N.  This 
latter  amount  of  fixation  can  hardly  be  regarded  as  significant  because 
increasing  the  quantity of  antibody  to  718  m/zg  N  did  not  increase  the 
amount  of fixation  (cf.  Fig.  3 a).  The  substitution  of  hog  A  -t-  H  blood 
group substance by human (MSM) as antigen or the use of human instead of 
guinea pig C' did not increase the amount of fixation by this antibody.  The 
intermediate fraction of the sucrose gradient obtained from the same GalNAc 
eluate (see Fig. 1) was rich in ~¢A antibody but it did not fix C'. The 7G con- 
tent of the GalNAc eluate from serum 1 was 46 % and with 322 m/zg N  about 
40 % fixation was found (Fig. 3 a). 
Fig. 3 b compares the C' fixation by'i'G GalNAc and 7G ARL0.52 antibodies 
from serum 1. The 7G GalNAc antibody is approximately three times better in 
complement fixation than the 7G AR~.0.52. 903 m#g N  of 7G AR~.0.52 were 
needed to fix approximately to the same extent as 290 m/zg N  of 7G GalNAc 
antibody. With 206 m/zg N, 7G GalNAc fixed over 50% while 213 m/,g N from 
7G ARL0.52 gave no fixation. 
Fig. 3 c gives the results obtained by C' fixation using the antibodies purified 
from Chris. serum, except for the 7M GalNAc which always lysed the controls 
with nonsensitized sheep red cells. The "i'M antibodies in the ARL0.52  eluate 
fix less C' than any of the 7G fractions from the same serum. With "yG anti- 
bodies the pattern observed is the reverse of that in serum 1; the 7G GalNAc 
antibody is not as good as the 7G AR,.0.52. 300 m/zg N  of 7G GalNAc eluate 
fixed only 40 %  C', as compared with the 58 % fixed with 260 m#g N  for the 
"yG ARL0.52  eluate. The capacities of different antibodies to fix C' are sum- 
marized in Table IV, columns five and six. Both Jos. and Chris. 7M GalNAc 
lysed sheep red cells  and  their capacity to fix C' cannot be estimated. Jos. 
7G GalNAc did not fix C' using 1060 m/zg N. The 7G ARL0.52 eluate from the 
same serum gave rather poor fixation (34 % with 940 m/zg N). Larger amounts 
of this antibody also lysed sheep red cells. 
To test the possibility that the incapacity of 7M  GalNAc antibody from 
serum  1  to fix C' was due  to a  property of the  antigen-antibody complex, 
rather than a lack of receptor for C' in the antibody itself, the direct hemolytic 
assay on A1 red blood cells was used. The results are given in Fig. 4 a. It is 
clear that the "},M GalNAc antibody has, on a weight basis, hemolytic activity 
comparable with that of the "yG AR~.0.52 eluate, but the 3'G GalNAc eluate is 
the best of the three. The whole GalNAc eluate was as good as 7G GalNAc 
antibody alone. On a molar basis, however, 7M GalNAc had somewhat better 
hemolytic activity than ~/G GalNAc. The  curves of lysis obtained with 7G 
and 7M  antibodies from serum 1 had a  tendency to stabilize at about 60 % 
hemolysis; for this reason a level of 40 % rather than 50 % lysis was used as the 
basis of comparison (see Table IV, last column). 
When ~¢G and ~,M antibodies from serum Chris. were studied in a  similar 
way  (Fig.  4 b),  it  was  seen  that  the  3'M  GalNAc  and  ~,M  ARL0.52 882  HUMAN  ANTIBODIES  AND  BLOOD GROUP  A  SUBSTANCE 
eluates lysed A1 human cells and the curves of lysis were absolutely superim- 
posable, but "yG GalNAc and ~G ARL0.52 eluates failed to lyse the cells with 
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Fro. 4. Hemolytic assay of purified anti-A antibodies: (a) Lysis of human At erythrocytes 
by antibodies from serum 1.5C'H50 ; 0.5 ml, RBC (4.4 X  10  T  cells/ml); total volume 1.25 ml, 
incubated I hr at 37°C.  (b) Lysis of human AI erythrocytes by purified antibodies from Chris. 
serum. 10C'H60 ; 1.0 ml At RBC (4.6 X  10  ~ ceUs/ml); total volume of 2.0 ml, incubated I hr 
at 37°C. (c) Lysis of sheep red cells by purified "rM antibodies from  Chris. serum.  2C'H~0; 
1.0 ml sheep RBC (2.0 X  105 cells/ml); total volume 2.0 ml, incubated 1 hr at 37°C. 
the amount of material used. Fig. 4 c shows that although the two "vM eluates 
were equally potent in lysing human A1 cells, the "rM  GalNAc  eluate was 
approximately four times better when tested against sheep red cens. 
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each eluate are presented in Figs. 5, 6, and 7 in which per cent inhibition is 
plotted against log inhibitor concentration. All eluates were tested with reduced 
pentasaccharide  ARL0.52,  trisaccharide  AsII  and  with  GalNAc.  Fig.  5 a 
shows  the inhibition curves of antiserum 1. The curves are nonlinear with a 
smooth slope indicating heterogeneity; this is particularly evident with penta- 
saccharide  ARL0.52.  Increasing  capacity  to  inhibit  precipitation  is  seen  in 
going from the mono-, to the tri-, to the pentasaccharide. In Fig. 5 b, inhibition 
assays on the GalNAc eluate of serum  1 show that the curve with ARL0.52 
reaches a plateau at 50 % inhibition. In Fig. 5 d, the data using the 7M GalNAc 
eluate from serum  1 are given. Significant inhibition was not obtained using 
as much as 4,920 m/zM of ARL0.52, 2,400 m#~ A~II; 107,000 m/~ GalNAc gave 
only 20 % inhibition. The limited quantities of ARL0.52 and AsII did not permit 
the use of larger amounts.  The ~,G GalNAc eluate of the same  serum gave 
inhibition curves with steep slopes, the AR~.0.52 being almost parallel to the 
AsII  curve  (Fig.  5 c).  Approximately  10  times more  trisaccharide A~II was 
necessary to reach equivalent inhibition and 11 times more GalNAc than AsII 
were needed for 50 % inhibition. In Fig. 5 e, the 3'G ARL0.52  eluate of serum 
1 shows  that good inhibition was  reached with both ARL0.52  and AsII, but 
extremely poor inhibition was seen with GalNAc. 
Fig. 6 gives the results for Jos. antiserum and its eluates. Jos. antiserum was 
not like serum  1 in that the curves of inhibition with AsII and AR~0.52  are 
very steep (Fig. 6 a). In Fig. 6 b, the 7G GalNAc eluate of Jos. gave inhibition 
curves quite similar to those for the 7G GalNAc eluate of serum 1 (Fig. 5  c), 
although higher concentrations of inhibitor (120 and 31,000 m/~ of ARr0.52 
and GalNAc  respectively were  required for 50%  inhibition).  The similarity 
between this eluate (Fig. 6 b) and the Jos. antiserum (Fig. 6 a) is striking. With 
the "yM GalNAc of Jos. very few points could be set up, owing to the scarcity 
of  the  oligosaccharides  and  the  very high  levels  of inhibitors  needed.  Sig- 
nificant inhibition with all three inhibitors was obtained; 800, 3,000, and 37,000 
m~M  gave 50%  inhibition with  ARL0.52, A6II,  and  GalNAc in  that  order; 
these figures must be only considered as rough estimates.  The  7G ARL0.52 
eluate of Jos. was inhibited only by AR~0.52 at a concentration comparable to 
the ~,G GalNAc eluate; 190 m#~ gave 50% inhibition. No substantial inhibi- 
tion was observed with AsII and GalNAc, although very high levels of inhibitor 
were used. 
Antiserum Chris.  (Fig.  7 a) resembled antiserum 1 in its inhibition curves, 
especially that with GalNAc. The ~/G GatNAc fraction (Fig. 7 b) differed from 
those of serum 1 and of Jos. in that ARL0.52 was not any better as an inhibitor 
than AsII. The ~G ARL0.52  eluate (Fig.  7 c)  was not inhibited by GalNAc 
and the inhibition by AsII and ARL0.52  was like that seen with whole serum 
(Fig.  7  a)  except that  the  curves  were  steeper.  Antiserum  Chris.  had  ~,lV[ 
antibodies  in  both  the  GalNAc  and ARL0.52  eluates.  Inhibition  assays  are CARLOS MORENO  AND ELVIN A. KABAT  885 
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given in  Figs.  7 d  and e respectively. They resemble each other in several 
respects. (a) ARID.52 is equally good as an inhibitor with both; (b) ~  does 
not inhibit at all in the range tested; (c) With GalNAc, the GalNAc eluate gave 
50% inhibition with 50,000 m/t~, while at this level the AR~0.52 eluate gave 
none. 
The studies of the antibodies by inhibition of precipitation are summarized 
in Table V. The figures correspond to the amount of oligosaccharide giving 50 % 
inhibition of precipitation. 
TABLE V 
Cwtlcen~ral~ion of Oligosaccharides Giving 50 Per Cent Inhib~n  of Prec@ila~ion of A~i-A 
Fractions by Human and Hog A Substance as Compared u,#h Ko by Equilibrium 
Dialysis 
Serum 
No.  1 
Jos. 
Chris. 
Antibody fraction 
~G GalNAc 
-/M GalNAc 
"rG AR~0.52 
"tG GalNAc 
~M GaINAc 
-~G ARL0.52 
"rG GalNAc 
~M GalNAc 
~/G ARL0.52 
~/M AR,O.52 
ARL0.52 
52 
>5000 
12 
120 
800 
190 
360 
1200 
180 
750 
Inhibitor (r-.-moles) 
AsH 
550 
>2400 
430 
450 
3000 
>900 
360 
>1400 
580 
>1400 
GaINAc 
6000 
> 107000* 
>34000 
31000 
37000 
>35000 
2200 
5OOOO 
>44000 
>65000 
Ko 
8XI0  4 
I X  I0  6 
2X  I0  s 
2X  10  ~ 
2X  I0  a 
5XI0  a 
* By extrapolation beyond the last point measured to 50~, a value of about 300,000 would 
be obtained. 
Studies by equilibrium dialysis on the purified antibodies are given in Figs. 
8, 9, and 10, corresponding to sera 1, Jos., and Chris. respectively. In each one 
of these the Scatchard (a) and Sips (b) plots are presented. The binding con- 
stants calculated from the Sips plot and the heterogeneity index "a" are given 
in each figure. 
?G GalNAc and "yG ARL0.52  eluates from serum I  (Fig. 8)  show binding 
constants of 8 X  104 and I  X  106 liters/mole erspectively; values well within ex- 
perimental  error.  The  ?G  ART.0.52 antibody was  less  heterogeneous  than 
"yG GalNAc. In the Scatchard plot, the values of r  can be extrapolated to 2. 
The ~M  GaINAc eluate of this serum was also studied, but no binding was 
obtained with it, indicating a very low constant of binding. 
Figure 9,  gives the data on the ~G eluates from Jos. serum. The binding 888  IiuMAN ANTIBODIES  AND  BLOOD  GROUP  A  SUBSTANCE 
constants, 2 X  103 and 2 X  1@ liters/mole  for the-yG GalNAc and 3'G AR~.0.52 
were substantially lower than those obtained with the antibodies from serum 
1. Both had 0.6 for the heterogeneity index. The low value of the binding con- 
stants together with the limited amount of antibody did not permit obtaining 
r values over one and extrapolation of the "yG GalNAc eluate was not possible. 
r/cxlO "4  Q 
o 
28- 
26- 
24- 
22- 
20- 
18- 
16- 
14- 
12- 
I0- 
8- 
6- 
4. 
2 
j  o./ 
•  7_'_  \Ko=,,,o, 
w=  _O  •  •  0=0.6 
•  YG Gel NAc  E/ubfe 
o  7G AR  L 0.52 Eluafe 
I  I  I  I 
I  1  2 
r  log c (,umole//iter) 
,og,-', 
-0.6 
-0.4 
-0,2 
-0 
-- 0.2 
-- 0.4 
-- 0.6 
FIO. 8. Scatchard (a)  and Sips (b) plots of equilibrium dialysis experiments with ~,G anti- 
bodies from serum 1 and ~[-I-ARL0.52 as hapten. 
Q 
e  YG Gel NAc  Etaote 
0.52 Eluofe  0  i. 
[  .=0.6  o/ 
•  \ 
! 
Ko=gx103 
i 
I  I  |  I  I  I 
I  2  0  I  2 
log c (,u mole/liter) 
r/cxlO" 4 
I0- 
9- 
8- 
7- 
6- 
5- 
4- 
3- 
R- 
I- 
0 
Iog  
-  0.2 
0 
-0.2 
-  -0.4 
-  -0.6 
--0.8 
-  -1.0 
-  -I.2 
Fro. 9. Scatchard (a)  and Sips (b) plots of equilibrium dialysis experiments with -/G anti- 
bodies from Jos. serum and 8H-ARL0.52  as hapten. CARLOS MORENO  AND ]~LVIN A. KABAT  889 
Chris. 7G ARL0.52 eluate (Fig. 10) had a constant K0 of 5 X  104, somewhat 
higher than that of the "IG GalNAc from the same serum (K0 --  2  X  104); 
both of these antibodies had an a value equal to 0.6. 
The light chains in these purified eluates were assayed by immunodiffusion 
against anti-K and anti-), antisera. The results  can be summarized  as follows: 
serum  1 7G GalNAc: mostly K determinants; serum  1 ~,M GalNAc:  mostly 
), determinants; serum I q,G AR~.0.52: K and ),. 
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FIG. I0.  Scatchard (s) and Sips  (b)  plots  of  equilibrium  dialysis  experiments  with vG anti- 
bodies  from Chris.  serum and 3H-ARL0.52 as  hapten. 
All the eluates from Chris. and Jos. antisera contained K  and k determinants 
in substantial amounts. The anti-A antibodies  even from purified eluates thus 
seem to be still heterogeneous  in this respect. 
DISCUSSION 
The procedure used to purify the antibodies from anti-A sera was designed 
to maximize the difference between the GalNAc and ARL0.52 eluates, especially 
with respect to the properties of the combining site. This was done by repeating 
the extraction with GalNAc until essentially all the antibody capable of being 
eluted  by  this  sugar  was taken out. Only then was elution with  ARL0.52 
attempted. Several properties of the antibodies and especially the findings with 
inhibition by oligosaccharides, must be interpreted on this basis. 
The GalNAc eluates always contained more antibody than did the ARL0.52 
eluates and the former were invariably more heterogeneous with respect to the 
classes of immunoglobulins  present (Tables II and HI). All of the GalNAc 
eluates contained "rM and ~G antibodies but only one AR~.0.52 eluate (Chris.) 89O  HUM.AN  ANTIBODIES  AND  BLOOD  GROUP  A  SUBSTANCE 
had  any 7M antibodies.  It is not possible to decide whether the other two 
individuals whose sera had no 7M in their ARL0.52 eluates had failed to make 
a 7M antibody of sufficient binding affinity to resist elution by GalNAc and 
yet be eluted by AR~.0.52, or whether  they made  7M  antibody  of  higher 
~ffinity  than  Chris.,  such  that  it was not eluted by the limited  amounts of 
AR,.0.52 used and remained on the column. Since "IM antibodies have a higher 
valence than 7G antibodies, a  given  concentration  of eluant  would tend  to 
elute the latter more rapidly than  the former,  assuming binding  sites of the 
same affinity. 
The total recovery from the column (Table II) was 72 % in the best case, and 
it was not possible to elute additional antibody with KI or KCNS  (35, 36). 
The recoveries of antibody are comparable to those obtained with antidextran 
eluted from Sephadex columns by isomaltose oligosaccharides  (37-39). 
The data on the purified antibody fractions (Table IV) show that there is no 
correlation between the hemagglutinating  capacity of a given antibody for A 
erythrocytes and whether it is "IG or 7M anti-A. With serum 1, more antibody 
N  was required  to give detectable hemagglutination  with  the  7M  GaINAc 
eluate than with the 7G GalNAc eluate, as had been found earlier for two other 
anti-A  sera  (5),  while  with Jos.  and  Chris.  the reverse was the case.  Other 
workers (4, 40-42) generally report 7M antibodies to be more potent in agglu- 
tination than 7G antibodies per unit weight, but in other instances,  the reverse 
has been found.  6 The current findings  with anti-A indicate that both types of 
behavior may occur within a single antigen-antibody system. 
It is especially significant, however, that with all three sera the hemagglutinat- 
ing  potency of the 7G  GalNAc antibody was always less  than  that  of the 
7G ARL0.52 eluate,  a  result in accord with the hypothesis that  the latter is 
eluting antibody with larger size combining sites and hence with higher affiuity. 
Although the purified  antibody solutions varied in precipitability by soluble 
blood group substance from 43-100%, it is not believed that the lower values 
represent impurities,  and all analyses are based on the total protein N  of the 
solutions.  On the micro scale used, solubility of antigen-antibody precipitates 
is appreciable (27) and this would tend to give low results. Moreover, serum 
proteins other than 7M, 7G, and 7A immunoglobulins would not be detected 
in irnmunoelectrophoresis.  By agar  diffusion  traces  of serum albumin  could 
sometimes be seen.  In  addition,  assays by radial  diffusion  showed  the 7M, 
"IG, and 7A in the GalNAc or ARL0.52 eluates to account for 100% of the 
protein. Finally, equilibrium dialysis data on the 7G GalNAc eluate of serum 1 
which showed the lowest amount of precipitable antibody gave an extrapolated 
valence of 2, based on total N  content indicating the absence of nonantibody 
protein. 
6  Schulkimi, M., M. Herzberg, and J. A. Robbins. 1968. Antibacterial antibodies. II. Speci- 
fic secondary biological properties of rabbit antibodies to Brucdla  abortus  and  Bordedega 
pcrtussis.  Submitted  for publication. CARLOS MOREN0  AND  ELVIIq A. KABAT  891 
With respect to C' fixing capacity, variations were also found even with the 
same class of antibody from a given individual.  The 7G GalNAc eluate from 
serum  1 was more potent in fixing  C' than  the 7G AR~.0.52 eluate, but the 
reverse was the case with Jos. and  Chris.  The basis for this variation is not 
clear, but could in part be related to differences in the 7G subclasses, since anti-A 
antibodies generally tend to be mixtures of various subclasses of 7G (43) and 
Ishizaka et al. (44) found differences in C' fixing potency of aggregated human 
myeloma globulins  of different 7G subclasses.  With  human  antidextran,  all 
of which was of the ~/G2 subclass (43), the antibody eluted by larger oligosac- 
charides was more potent in C' fixation than that eluted with smaller oligosac- 
charides (38). 
An unusual specificity difference  was also noted between the 7M GalNAc 
and -yM ARL0.52 eluates of Chris.  While both were equally potent in lysis of 
human A, erythrocytes, the former was four times better in lysing sheep ery- 
throcytes. This difference may provide another parameter of heterogeneity of 
7M antibodies and could also throw light on the nature of the human A-sheep 
erythrocyte Forssman antigen system (45, 46). The capacities of the antibody 
fractions to fix C' with soluble blood group substances and to hemolyze human 
A, cells in the presence of complement did not correlate. In hemolysis, the 7M 
eluates were always better than the ~G eluates on a molar basis, whether or 
not they were poorer in C' fixation.  The hemolysis of an erythrocyte generally 
requires a single molecule of 7M antibody to fix C'la on to the surface of an 
erythrocyte, while it is thought that two 7G antibody molecules must be at the 
same site for hemolysis to occur (12).  The differences  between 7M and  ?G 
noted in this study for serum 1 are relatively small,  while with Chris.  they 
are very great. Thus, the major factor involved in variations in hemolysis as in 
C' fixation  is probably ascribable largely  to  antibody heterogeneity in  the 
7M, as well as in the 7G fractions. Plotz et al.  (47) have described a mouse 
7M antibody unable to fix C', and Hoyer et al. (48) found that only 21 To of a 
rabbit ~M antiazobenzenearsonate antibody was capable of fixing C'la. 
Ishizaka et al.  (49), studying rabbit anti-A, found that 7G was better than 
7M when tested by C' fixation using soluble antigen, but the reverse was true 
when the test was done with red blood cells or insoluble PLA blood group sub- 
stance as antigen,  indicating that the capacity of a  given antibody to fix C' 
is a property that can depend on the physical state of the antigen, as is also 
supported by our data using hemolysis and C' fixation. 
A  most  important  finding  is  the  fractionation  of anti-A  antibodies  with 
respect to the sizes of their combining sites as measured by differences in their 
relative  capacity to be inhibited  by small as compared with  large  oligosac- 
charides.  It  was to be expected that  after  the prior  extensive elution with 
GalNAc, the ARL0.52 eluates would be relatively poorly, if at all, inhibited by 
GalNAc, and this turned out to be so in all instances.  The ARL0.52 eluates were 
only inhibited by AR~.0.52, and  in some instances, by the trisaccharide AsII. 892  trUM_AN  ANTIBODIES  AND  BLOOD  GROUP  A  SUBSTANCE 
With serum Chris. this was true for the 7M eluates as well as the 7G eluates. 
These data do not imply that GalNAc does not inhibit but only that it is at a 
very great competitive disadvantage in displacing the A determinants on the 
polyvalent A macromolecule. The findings with the ~rM eluates of Chris. show 
that 7M sites may be complementary to sizes larger than a  monosaccharide 
and thus may not differ significantly in the sizes  of their determinants from 
those of 7G antibodies. 
All 7M anti-A fractions studied required larger concentrations for inhibition 
than did the corresponding 7G antibodies from the same individual. With the 
eluates from Jos., the concentrations of all three oligosaccharides needed for 
50 % inhibition were one order of magnitude greater than with the 7G eluates. 
In studies in other systems, Jaton et al.  (50)  reported that precipitation by 
antigen of 7M and ~G anti-uridine antibodies prepared to artificial uridine- 
containing proteins was equally well inhibited by uridine, but Groff et al. (51) 
with phenylarsonate antibodies found about  10-fold  higher concentrations of 
phenylarsonate analogues  were  needed  to  give  comparable  inhibition  with 
~M than with 7G antibodies. 
With all 7G  eluates, except the Jos. 7G ARL0.52,  the inhibition by  AsII 
was relatively constant, the amount needed for 50% inhibition ranging from 
360  to 580  m/~,  while in  simultaneous assays the corresponding values for 
AR~.0.52 varied from 12 to 360 m/~. A~II differs from AR~.0.52 in two important 
respects:  (a)  it  lacks  the  fucose substitution  on  the  subterminal  galactose; 
(b)  it  is  a  type  1  determinant  (52)  being  linked ~-D-Gal-(1--~ 3)-D-GNAc 
while the ARL0.52, a type II determinant is ~-D-Gal-(1 --~ 4)-D-GNAc. Whether 
the uniformity of the inhibition with AsII represents a uniform contribution of 
its three sugars to the total energy of binding or is due to chance is not known. 
Another major finding is that, for each individual, the binding constants of 
the ARL0.52 eluates were higher than those for the GalNAc eluates, although 
the values with serum  1 are very dose. This parallels the findings with the 
inhibition data and is what one would expect on the hypothesis that the ARL0.52 
antibodies had larger size combining sites. 
The values of the  association constants,  with one exception, 2-10  X  1@ 
are generally on the low side of those reported for many systems but are only 
slightly lower than the values found by Karush (53) of 1 and 2 X  105 for anti- 
Lac antibodies and of the same order as those 8-20 X  104 found for rabbit and 
horse  type VIII  antipneumococcal antibodies by Pappenheimer  et  al.  (54). 
Jaton et al. (50) reported 5.6 X  1@ for the association constant of anti-uridine 
antibodies. The Jos.  7G GalNAc eluate gave an extraordinarily low value of 
2 X  108. The heterogeneity index in the Sips plots were still very low indicating 
substantial heterogeneity in the eluates. These values and those of Pappen- 
heimer et al. (54) and Merler et al. (55) represent the first measurements with 
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Values for binding constants of anti-A and anfi-B based on measurements of 
direct binding of ~M and ~G antibody to erythrocytes have also been published 
(56-58).  These values tend to be much higher than those reported here, but 
since they are based on heterogeneous systems and both the antigen and anti- 
body are multivalent, they are not measuring the same property. 
$~kRY 
Human antibodies to blood group A substance were purified by absorption 
on columns of insoluble polyleucyl hog blood group A  -4-  H  substance and 
eluted first with N-acetylgalactosamine and then with an A  active reduced 
pentasaccharide AR~.0.52. The ~M and ~'G antibodies in these eluates were 
separated by density gradient centrifugation. The antibodies were studied for 
their relative capacities to be inhibited by various blood group A active oligo- 
saccharides.  Antibodies  eluted  by  the  N-acetylgalactosamine could  be  in- 
hibited  by N-acetylgalactosamine, as  well  as by  lower concentrations of A 
active tri-  and pentasaccharides, while those eluted by the pentasaccharide 
AR~0.52  could  only be  inhibited  by  the  two  oligosaccharides,  but  not  by 
N-acetylgalactosamine, indicating that the N-acetylgalactosamine duate had 
more antibodies with smaller size  combining sites than the ARt0.52  eluate. 
Measurements by equilibrium dialysis gave values ranging from 2  X  103 to 
1 X  105 M  --1 and the values obtained with the ARt0.52 eluate were somewhat 
higher than those with the GalNAc eluate. Only one of three anti-A sera had 
"yM anti-A in the ARt0.52  eluate, while all three had ~M in the N-acetyl- 
galactosamine eluate.  Data  on  the precipitating,  hemagglutinating, comple- 
ment fixing, hemolytic properties of the eluted antibodies, and of their content 
of K and X light chains are given. 
BIBLIOGRAPHY 
1. McDu~e, F. M., P. Z. Alien, E. A. Kabat, and C. A. Williams, Jr. 1958. An im- 
munochemical study of the rdationship of human blood group isoantibodies to 
~,1 and ~,2 globulins. J. Imm~mol. 81:48. 
2.  Abelson, N. M., and A. S. Rawson. 1959. Studies  of blood group  antibodies.  I. 
Fractionation of anti-A and anti-B isohemagglutinins by anion-cation cellulose 
exchange chromatography. Y. Immunol. 89.:435. 
3. Kunkel, H.  G., and  J.  H.  Rockey.  1963. ~  and  other immunoglobulins in 
isolated  anti-A antibodies. Proc. Soc. Exp. Biol. Med. 113:278. 
4.  Ishizaka, K., T. Ishizaka, E. H. Lee, and H. H. Fudenberg. 1965. Immunochemical 
properties  of human 7A isohemagglutinin.  I.  Comparison with ~'G and ~,M 
globulin antibodies. Y. Immunol. 95:197. 
5.  Kaplan, M. E., and E. A. Kabat. 1966. Studies on human antibodies. IV. Purifica- 
tion and properties  of anti-A and anti-B  obtained by absorption  and elution 
from insoluble blood group substance, ft. Exp. IVied. 123:1061. 
6.  Fahey, J., and E. Morrison.  1960. Separation  of 6.6S and 18S gamma globulins 
with isohemagglutinin activity. Y. Lab. Clln. Med. §5:912. 894  huMAN  ANTIBODIES AND BLOOD GROUP A  SUBSTANCE 
7.  Tonder, O., and F. Milgrom.  1966. Studies  on agglutination by macromolecular 
antibodies. III. Agglutination by natural isoanfibodies.  Fox Sang. 11:475. 
8.  Hasekura, H., and T. Ishimori. 1966. Characteristics of IgG, IgA and IgM ABO 
blood  group  antibodies.  Their  haemolytic  activities  and  stability  to  heat 
neutralization or mercaptoethanol treatment. Proc. Jap. Acad. 42:833. 
9.  Goodman, H. S. 1962. Analysis of the immune agglutination of red cells. Trans- 
plantation. 2:327. 
10.  Ishizaka, T., K. Ishizaka, T. Borsos,  and H. Rapp. 1956. Cq fixation by human 
isoagglutinins:  fixation of Cq by 3'G and TM but not by TA antibody. J'. Ira- 
muncl.  97:716. 
11.  Goodman, H. S.  1958. The comparison of complement fixing and hemolytic ac- 
tivities in several systems. J. Infec. Dis. 103:278. 
12.  Borsos, T., and H. Rapp. 1965. Complement fixation on cell surfaces by 19S and 
7S antibodies. Science 150:505. 
13.  Ovary, Z., H. Fudenberg, and H. G. Kunkd. 1960. Anaphylactic reactions in the 
skin of the guinea pig with high and low molecular weight antibodies and gamma 
globulins. J. Exp. Med. 112:953. 
14.  Tsuyuki, H., H. VanKley, and M. A. Stahmarm. 1956. The preparation and phys- 
ical properties of polypeptidyl proteins. J. Amer. Chem. Soc. 78:764. 
15.  Kabat, E. A., and A. E. Bezer. 1945. Immunochemical studies on blood groups. I. 
Estimation of A and B isoantibodies in human serum by the quantitative pre- 
dpitin method. J. Exp. Meal. 82:207. 
16.  Alien, P. Z., and E. A. Kabat. 1958. Persistence of circulating antibodies in human 
subjects immunized with dextran, levan and blood group substances. ]. Im- 
munol. 80:495. 
17.  Schiffman,  G., E. A. Kabat, and S. Leskowitz. 1962. Immunochemical studies on 
blood groups. XXVI. The isolation of ollgosaccharides from human ovarian cyst 
blood group A  substance including  two disaccharides  and a  trisaccharide in- 
volved in  the  specitidty  of  the  blood  group  A  antigenic  determinant.  J. 
Amer. Chem. Soc. 84:73. 
18.  Watkins, W. M., and W. T. J. Morgan.  1952. Neutralization of the anti-H ag- 
glutinin in eel serum by simple sugars. Nature (London). 169:825. 
19.  Cazal,  P.  and  M.  Lalaurie.  1952. Recherches sur  quelques  phyto-agghitinines 
specitiques des groupes sanguins ABO. Acta Haematol. 8:73. 
20.  Kabat, E. A. 1956. Blood Group Substances. Academic Press, Inc., New York. 
21.  Schiffman, G., E. A. Kabat, and W. Thompson. 1964. Immunochemical studies on 
blood groups. XXX. Cleavage of A, B and H blood-group substances by alkali. 
Biochemistry. 3:113. 
22.  Lloyd, K. O., and E. A. Kabat. 1964. Some products of the degradation of blood 
group substances by alkaline borohydride.  Biochem.  Biophys.  Res.  Commun. 
16:385. 
23.  Lloyd, K. O., E. A. Kabat, E. J. Layug, and F. Gruezo.  1956. Immunochemical 
studies on blood groups. XXXIV. Structures of some oligosaccharides produced 
by alkaline degradation of blood group A, B and H  substances.  Biochemistry. 
5:1489. 
24.  Lloyd, K. O., and E. A. Kabat. 1967. Immunochemical studies on blood groups. 
XXXVI. The nature of the unsaturated residue  in some oligosaccharides  pro- CARLOS MORENO AND ELVIN A.  KABAT  895 
duced by the action of sodium hydroxide-sodium borohydride on blood group 
A, B and H substances, Carbohyd. Res. 4:165. 
25.  Schiffman, G., E. A. Kabat, and S. Leskowitz.  1960. Immunochemical studies on 
blood groups. XXIV. Some oligosaccharides isolated from dialysates after mild 
acid hydrolysis of human blood group B substances from ovarian cyst fluid..L 
Amer. Chem. Soc. 82:1122. 
26. DuBois, M., K. A.  Gilies, J. K. Hamilton, P. A. Rebers, and F. Smith. 1956. 
Colorimetric method for determination of sugars and related compounds. Ana/. 
Chem. 28:350. 
27. Kabat,  E.  A.  1961.  Kabat  and  Mayer's  Experimental  lmmunochemistry. 
Charles C Thomas, Springfield, Ill., 2rid edition. 
28. Kunkel, H. G.  1959. Macroglobuiins  and  High  Molecular Weight  Antibodies 
in the Plasma Proteins. F. W. Putnam, editor, Academic Press Inc., New York. 
225. 
29. Bray, G. A. 1960. A simple efficient liquid scintillator for counting aqueous solu- 
tions in a liquid scintillation  counter. Anal. Biochem. 1:279. 
30.  Mancini, G., J. P. Vaerman, A. O. Carbonara, and J. F. Heremans. 1964. Protides 
of Biological Fluids,  H. Peeters, editor.  Elsevier Publishing  Co., Amsterdam, 
Netherlands. 2"370. 
31. Manciui, G., A. O. Carbonara, and J. F. Heremans. 1965. Immunochemical quanti- 
t~tion of antigens by siugle radial immunodittusion.  Immunochemistry.  2:235. 
32.  Grabar, P., and C. A. Williams, Jr. 1953. M6thode permettant l'6tude conjug6 
des propri6t& 61ectrophor6tiques et immunochemiques  d'un m~lange des pro- 
teines. Application au serum sauguin. Biochim.  Biophys. Acta. 10:193. 
33. Mayer, M.  M.  1961. Kabat  and  Mayer's  Experimental  Immunochemistry. 
Charles C Thomas, Springfield, Ill., 2rid edition. 133. 
34. Wasserman,  E., and L. Levine. 1961. Quantitative microcomplement fixation and 
its use in the study of antigenic structure by specific antigen-antibody inhibi- 
tion. J. Immunol. 87:290. 
35. Avrameas,  S., and T. Temynck. 1967. Use of iodine salts in the isolation of anti- 
bodies and the dissolution of specific immune precipitates Biochera. J. 102.37c. 
36. Davrlliker,  W., R. Alonso, V.  de Saussure,  F. Kierszenbaum, S. Levison, and 
H. Shapiro.  1967. The effect of chaotropic ions on the dissociation of antigen- 
antibody complexes, Biochemistry. 6: 1460. 
37.  Schlossman, S., and E. A. Kahat. 1962. Specific fractionation of a population of 
antidextran molecules with combining sites of various sizes. J. Exp. Med. 116: 
535. 
38.  ~lzer, J., and E. A. Kabat. 1964. Specific iractionation of human antidext~an 
antibodies.  II. Assay of human antidextran sera and specifically fractionxted 
purified antibodies by microcomplement fixation and complement fixation in- 
hibition techniques. J'. Exp. Med. 119.'983. 
39.  C~lzer, J., and E. A. Kabat.  1964. Specific fraction&tion of human antidextran 
antibodies.  III.  Fractionation of  antidextran  by  sequential  extraction with 
oligosaccharides of increasing  chain length and attempts at subfractionation. 
Immunochemistry.  1.303. 
40.  Osier, A., J. Mulligan,  and I. Rodriguez.  1966. Weight estimates of rabbit anti- 896  HUMAN  ANTIBODIES AND  BLOOD  GROUP  A  SUBSTANCE 
human serum albumin based on antigen-binding and precipitin analysis: specific 
hemagglufinating activities of 7S and 19S components. J. Immunol.  96:334. 
41.  Pike,  R. M.  1967. Antibody heterogeneity and  serological  reactions.  Bacterial. 
Rev. 31:157. 
42.  Robbins, J., K. Kenny, and E. Suter. 1965. The isolation and biological activities 
of rabbit TM and 7G anti-Salmonella typhimurium  antibodies. J.  Exp.  Med. 
122:385. 
43.  Yount, W. J., M. M. Dorner, H. G. Kunk¢l, and E. A. Kabat. 1968. Studies  on 
human antibodies. VI. Selective variations in subgroup composition and genetic 
markers. J. Exp. Med. 127:633. 
44.  Ishizaka, T., K. Ishizaka, S. Salmon, and H. Fudenberg. 1967. Biological activities 
of aggregated 3, globulins.  VIII. Aggregated immunogiobulins  of different clas- 
ses. J. ImmunoL 99:82. 
45.  Diehl,  J.,  and  M.  Mallete.  1964. Nature  of the  Forssman hapten from sheep 
erythrocytes. J. Immunol.  93:965. 
46.  Flory, L. L. 1968. Relationship between anti-A and anti-Forssman. Immunology. 
14:787. 
47.  Plotz, P., H. Colten,  and N. Talal. 1958. Mouse macrogiobulin antibody to sheep 
erythrocytes, a non-complement-fixing  type. J. Immunol.  100:752. 
48.  Hoyer, L., T. Borsos,  H. Rapp, and W. Vannier.  1968. Heterogeneity of rabbit 
IgM antibody as detected by C'la fixation. J. Exp. Med. 127:589. 
O.  Ishizaka, T., T. Tada, and K. Ishizaka. 1968. Fixation of C' and C'la by rabbit 
7G and 7M  antibodies  with  particulate  and  soluble  antigens.  J.  ImmunoL 
100:1145. 
50.  Jaton, J., H. Ungar-Waxon,  and M. Sela. 1967. Comparison of IgG and IgM anti- 
bodies specific for uridine.  Eur. J. Biochem. 2:106. 
51.  Groff, J., J. Ferber, and S. Shulman.  1967. Inhibitory effect of analogues of phenyl- 
arsonate  on  purified  19S  and  7S  antibodies  specific  for  azophenylarsonate. 
Immunology. 12:216. 
52.  Rege, V. P., T. J. Painter, W. M. Watkins, and W. T. J. Morgan. 1963. Three new 
trisaccharides  obtained from human blood group A,  B  and  Le  a substances: 
possible sugar sequences in the carbohydrate chains. Nature (London). 200:532. 
53.  Karush, F. 1957. Interaction of purified anti-fl-lactoside  antibody with haptens. 
J. Amer.  Chem. Soc. 79:3380. 
54.  Pappenheimer, A.,  W. Reed, and R. Brown.  1968. Quantitative studies of the 
specificity of anti-pneumococcal polysaccharide antibodies types III and VIII. 
III. Binding of labelled oligosaccharides  derived from $8 by anti-S8 antibodies. 
J. Immunol.  100:1237. 
55.  Merler, E., L. Karlin, and S. Matsumoto. 1968. The valency of human ~/M im- 
mtmoglobulin antibody. J. Biol. Chem. 243:386. 
56.  Economidou, J., N. Hughes-Jones, and B. Gardner. 1967. Quantitative measure- 
ments concerning  A and B antigen sites.  Vox Sang. 12:321. 
57.  Economidou, J., N. Hughes-Jones, and B. Gardner. 1967. The functional activities 
of IgG and IgM anti-A and anti-B. Immunology. 13:227. 
58.  Economidou, J., N. Hughes-Jones, and B. Gardner. 1967. The reactivity of sub- 
units of IgM anti-B. Immunology. 13:235. 